Benzinga | Apr 28, 2021 07:58AM EDT

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 Cream in a Phase 2 Trial for Epidermolysis Bullosa

* Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 cream

* Additional submissions slated for France, Germany, Greece, and Italy over the next several days and weeks.

* Anticipated study on track to begin in 3Q 2021